DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
Add patients with power kidney illness with or without diabetes to the rising list of those who win proven have the benefit of therapy with an SGLT2 inhibitor. Within the DAPA-CKD trial, therapy with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin…